My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Denosumab Biosimilar, RANKL Monoclonal Antibody

Denosumab Biosimilar, RANKL Monoclonal Antibody

Anti-RANKL Human Monoclonal Antibody

Catalog No. Product Name Size List Price (US$) Quantity
C004P Denosumab Biosimilar, Human RANKL Monoclonal Antibody 1 mg 125.00
C004P Denosumab Biosimilar, Human RANKL Monoclonal Antibody 5 mg 500.00
C004P Denosumab Biosimilar, Human RANKL Monoclonal Antibody 20 mg 1000.00
C004P.LA Denosumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant 1 mg 650.00
C004P.h1 Denosumab Biosimilar, Human IgG1 1 mg 650.00
C004P.NA Denosumab Biosimilar, N297A Mutant 1 mg 650.00
Description

C004P: Denosumab Biosimilar, Human RANKL Monoclonal Antibody

Recombinant Humanized IgG2 Monoclonal Antibody.
Isotype: Human IgG2 kappa.
Source: The monoclonal antibody denosumab biosimilar was produced in the denosumab biosimilar CHO stable cell line.
Specificity/Sensitivity: The monoclonal antibody denosumab biosimilar specifically binds to the human RANKL (RANK ligand) protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by denosumab.
Form of Antibody: 0.2 uM filtered solution, pH 5.2, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The monoclonal antibody denosumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

Denosumab, a fully human monoclonal antibody, inhibits the RANKL (RANK ligand) protein, the primary signal for bone removal. Denosumab can be used for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.

Syd Labs also provides the following research grade antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade (VEGF-A)
Ranibizumab Biosimilar, research grade (VEGF-A, Fab produced in E. coli)
Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Infliximab biosimilar, research grade (TNF alpha)
Adalimumab biosimilar, research grade (TNF alpha)
Rituximab biosimilar, research grade (CD20)
Denosumab biosimilar, research grade (RANKL, RANK ligand, OPGL, TNFSF11, CD254, TRANCE, ODF)
Palivizumab Biosimilar, research grade (RSV)
Omalizumab biosimilar, research grade (IgE)
Eculizumab biosimilar, research grade (C5)

Related Links

See our Privacy Policy